Monday, December 23, 2024
HomeTagsBOS

BOS

AI Therapeutics Announces Investigator Initiated Phase 2 Trial at UCSF to Study LAM-001 in Patients With Bronchiolitis Obliterans Syndrome (BOS) Post-Lung Transplant

AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the commencement of an investigator initiated Phase 2 study...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics